Grand Opening, Exhibit & Poster Presentations -
Session I Viewing
13:00-13:30
Welcome from the ISPOR President
Michael Drummond PhD,
ISPOR 2006-2007 President and Professor, University of
York, York, UK
Introduction and Congress Objectives Program Committee Co-Chairs: Ivar Sønbø Kristiansen MD,
MPH, PhD, Professor, Institute of Health, University
of Oslo, Oslo, Norway Bengt Jønsson PhD, Professor of Health
Economics, Stockholm School of Economics, Centre for
Health Economics, Stockholm, Sweden
13:30-15:00
FIRST PLENARY SESSION
"HEALTH TECHNOLOGY ASSESSMENT (HTA) AS A BASIS
FOR REIMBURSEMENT AND PRIORITIES IN HEALTH CARE"
Moderator: Bengt
Jønsson PhD, Professor of Health Economics, Stockholm
School of Economics, Centre for Health Economics,
Stockholm, Sweden
13:30-13:40
Introduction
Speaker: Bengt Jønsson PhD,
Professor of Health Economics, Stockholm School of
Economics, Centre for Health Economics, Stockholm,
Sweden
13:40-14:10
HTA as a Basis for Reimbursement and Priorities in
Health Care: European and Industry Perspective Speaker: Richard Bergström MScPharm,
Managing Director, Swedish Association of the
Pharmaceutical Industry, Stockholm, Sweden
Richard Bergstrom will present the HTA principles
adopted by EFPIA and describe the approach that the
European industry is taking to promote good use of HTA.
This will include an update on industry’s input to the
EU High Level Group Pharmaceutical Forum.
14:10-14:40
Priority Decisions - The Authority Challenge Speaker: Audun Hågå MSc, Deputy Director
General, Ministry of Health, Oslo, Norway
"Priority decisions - the authority challenge" - Given
that it is not possible for society to cover what the
individual patient regards as "best possible treatment"
in all fields, the authority challenge is to make good
priority decisions. This will balance the needs and
secure "best possible" treatment for as many as
possible. What are the implications when it comes to
reimbursement of pharmaceuticals?
W2: THEORETICAL & PRACTICAL ISSUES IN THE CALIBRATION OF
PHARMACOECONOMIC MODELS DISCUSSION LEADERS: Douglas CA. Taylor, MBA, Director,
Health Economics and Outcomes Research, i3 Innovus,
Medford, MA, USA; Denise Kruzikas, PhD, U.S. Health
Outcomes, GlaxoSmithKline, Philadelphia, PA, USA; David
Thompson, PhD, Vice President, Global Health Economics,
i3 Innovus, Medford, MA, USA
W6: VALUING EQ-5D HEALTH STATES : PAST PRACTICE AND
FUTURE POSSIBILITIES DISCUSSION LEADERS: Paul Kind, Principal Investigator,
University of York, York, United Kingdom; Frank De Charro,
Executive Director, EuroQoL Group, Rotterdam, Netherlands;
BA Van Hout, PhD, Professor, University Medical Center
Utrecht, Utrecht, Netherlands
Break, Exhibits & Poster
Presentations Viewing – Session I
17:00-18:00
Workshops Session II (7 workshops)
ECONOMIC STUDY METHODS
W8: DESIGN ISSUES FOR HEALTH ECONOMICS IN POST-LAUNCH
REAL WORLD STUDIES DISCUSSION LEADERS: Mike Drummond, DPhil, Professor of
Health Economics, University of York, York, Heslington,
United Kingdom; Deborah Marshall, PhD, Vice President,
Global Health Economics and Outcomes, i3 Innovus,
Burlington, ON, Canada; Daniela Belovich, MSc, Project
Manager, i3 Innovus, Burlington, ON, Canada
W9: DEVELOPING ECONOMIC MODELS: PREDICTING CHANGE OVER
TIME WITH FRACTIONAL POLYNOMIALS DISCUSSION LEADERS: K Jack Ishak, PhD, Statistician, Caro
Research Institute, Montreal, QC, Canada; J. Jaime Caro,
MDCM, FRCPC, FAC, President & Scientific Director, Caro
Research Institute, Concord, MA, USA; Irina Proskorovsky,
BSc, Statistician, Caro Research Institute, Dorval, QC,
Canada
W11: NEW DEVELOPMENTS IN DATA MINING: DIGGING INTO
OBSERVATIONAL DATABASES AND ITS USE IN DRUG SAFETY
SURVEILLANCE DISCUSSION LEADERS: Charles M Gerrits, MS, PharmD, PhD,
Head - Global Pharmacoepidemiology & Outcomes Research,
Takeda Global Research & Development, Lincolnshire, IL,
USA; Andrew Bate, MA, PHD, Manager - Research
Methodologies, WHO Collaborating Centre for International
Drug Monitoring, Uppsala, Sweden; Manfred Hauben, MD, MPH,
Medical Director - Risk Management Strategy, Pfizer Inc,
New York, NY, USA
W12: COMMONALITIES AND DISSIMILARITIES BETWEEN EUROPEAN
OBSERVATIONAL DATASETS DISCUSSION LEADERS: John Parkinson, PhD, Head GPRD, MHRA,
MHRA, London, UK, United Kingdom; Miriam Sturkenboom, PhD,
Associate Professor, Erasmus University Medical Centre,
Rotterdam, Netherlands; Tjeerd P Van Staa, MD, PhD, Head
of Research, General Practice Research Database, London,
United Kingdom
